Reactive astrocytes promote proteostasis in Huntington’s disease through the JAK2-STAT3 pathway

Authors:
Publisher website
Google Scholar
Abstract
Huntington’s disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington’s disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington’s disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington’s disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington’s disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington’s disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.
All Related Versions
Funding Information
  • French National Research Agency (ANR-11-EQPX-0029, ANR-10-INBS-04, ANR-11-IDEX-0003-02, ANR-10-INBS-09, 2010-JCJC-1402-1, 2011-BSV4-021-03, ANR-16-TERC-0016-01, ANR-20-CE16-0012-02to C.E., 2011-INBS-0011, ANR-17-CE12-0027, H2020 ERA-N, ANR-17-RAR3-0008-01)
  • Fondation Maladies Rares
  • Association Huntington France
  • Région Ile-de-France
  • Fondation pour la Recherche Médicale fellowship (ARF201909009244)

This publication has 74 references indexed in Scilit: